$1,160,000 of ABBVIE INC. lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property S. 864, HELP Copays Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act S. 2903, Safe Step Act H.R. 5509, Safe Step Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Issues related to data privacy Issues related to Hepatitis C elimination Issues related to FDA communications Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 Public Law No: 119-21 (formerly known as H.R. 1, One Big Beautiful Bill Act) Implementation Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program Issues related to antitrust and competition policy Issues related to pharmaceutic tariffs and unfair trade practices Issues related to U.S. biotech competitiveness with China"
You can find more data on corporate lobbying on Quiver Quantitative.
ABBV Congressional Stock Trading
Members of Congress have traded $ABBV stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 05/05.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
ABBV Insider Trading Activity
ABBV insiders have traded $ABBV stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:
- PERRY C SIATIS (EVP, GC AND SECRETARY) has made 0 purchases and 3 sales selling 18,668 shares for an estimated $4,375,549.
- DAVID RYAN PURDUE (SVP, Controller) sold 5,230 shares for an estimated $1,221,518
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
ABBV Hedge Fund Activity
We have seen 1,776 institutional investors add shares of ABBV stock to their portfolio, and 1,703 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC removed 12,202,446 shares (-48.5%) from their portfolio in Q1 2026, for an estimated $2,642,195,632
- FISHER ASSET MANAGEMENT, LLC added 8,463,716 shares (+1347.0%) to their portfolio in Q1 2026, for an estimated $1,832,648,425
- WELLINGTON MANAGEMENT GROUP LLP removed 8,028,867 shares (-53.8%) from their portfolio in Q1 2026, for an estimated $1,738,490,571
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN removed 7,827,781 shares (-87.8%) from their portfolio in Q1 2026, for an estimated $1,694,949,419
- CAPITAL RESEARCH GLOBAL INVESTORS added 5,846,586 shares (+23.0%) to their portfolio in Q1 2026, for an estimated $1,265,961,266
- DIAMANT ASSET MANAGEMENT, INC. added 3,654,351 shares (+21649.0%) to their portfolio in Q1 2026, for an estimated $791,276,622
- UBS GROUP AG added 3,524,276 shares (+33.5%) to their portfolio in Q1 2026, for an estimated $763,111,482
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
ABBV Price Targets
Multiple analysts have issued price targets for $ABBV recently. We have seen 11 analysts offer price targets for $ABBV in the last 6 months, with a median target of $265.0.
Here are some recent targets:
- Vamil Divan from Guggenheim set a target price of $261.0 on 07/09/2026
- Chris Schott from JP Morgan set a target price of $280.0 on 07/09/2026
- Carter Gould from Cantor Fitzgerald set a target price of $265.0 on 07/06/2026
- Gary Nachman from Canaccord Genuity set a target price of $273.0 on 06/23/2026
- David Amsellem from Piper Sandler set a target price of $298.0 on 06/23/2026
- Gavin Clark-Gartner from Evercore ISI Group set a target price of $235.0 on 05/15/2026
- Terence Flynn from Morgan Stanley set a target price of $278.0 on 04/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
